companiesCompany

Citius Pharmaceuticals

Citius Pharmaceuticals brought denileukin diftitox back to market as Lymphir, approved in 2024 for relapsed cutaneous T-cell lymphoma, through its Citius Oncology subsidiary.

Citius licensed the reformulated denileukin diftitox (E7777) from Eisai in 2021 and secured FDA approval in August 2024 for adults with relapsed or refractory stage I to III cutaneous T-cell lymphoma after at least one systemic therapy.

Headquarters

Cranford, New Jersey, US

Scorecard

All companies

#110of 680 companies, score 23

approved products +6
targets +2
modalities +2
regions +1
registry trials +12

1 approved, 0 in phase 3, 0 earlier, 1 targets, 35 registry studies. Formula on the scorecards page.

Type

biotech · CTXR

Stage

Public

Website

www.citiuspharma.com

Products

1top

ApprovedIL-2 receptor-directed cytotoxin (fusion protein)

Denileukin diftitox · Lymphir

Denileukin diftitox (Lymphir) is an infusion that uses the interleukin-2 signal as a homing device to deliver a bacterial toxin into cutaneous T-cell lymphoma cells. It was withdrawn in 2014 and returned in an improved form in 2024.

Connected